The period for CME/CE credit for this activity has expired.


This activity has expired. Thank you for using WebBasedCME.com. Continue to check our activities page for additional online CME offerings .


Demographic Questionnaire - Cardiometabolic Risk Reduction in the Metabolic Syndrome and Type 2 Diabetes

1.What is your profession? Check all that apply.
 
MD
DO
RN
NP
PA
PharmD
RPh
Other

2.Are you currently a practicing clinician?
 
Yes
No

3.What is your specialty? Check all that apply.
 
Primary Care
Endocrinology
Cardiology
Clinical nutrition
Other

4.How many patients do you see on an average weekly basis?
 
< 50
50 - 100
100 - 150
> 150

5.Which of the following measures do you use to evaluate body weight and/or body composition in your clinical practice? Check all that apply.
 
Body weight
Body-mass index
Waist circumference
Visual inspection for abdominal obesity

6.What percentage of your patients are overweight (based on body mass index [BMI] >25 kg/m2)?
 
0%-25%
26%-50%
51%-75%
76%-100%
Not applicable

7.What percentage of your patients are obese (based on BMI >30 kg/m2)?
 
0%-25%
26%-50%
51%-75%
76%-100%
Not applicable

8.What is your preferred treatment for overweight patients (BMI > 25 kg/m2) who DO NOT have any comorbidities?
 
Therapeutic lifestyle change
Orlistat
Sibutramine
Weight-loss surgery
Not applicable

9.What is your preferred treatment for overweight patients (BMI > 25 kg/m2) who have comorbidities (eg, dyslipidemia)?
 
Therapeutic lifestyle change
Orlistat
Sibutramine
Weight-loss surgery
Not applicable

10.What is your preferred treatment for obese patients (BMI > 30 kg/m2) who DO NOT have any comorbidities?
 
Therapeutic lifestyle change
Orlistat
Sibutramine
Weight-loss surgery
Not applicable

11.What is your preferred treatment for obese patients (BMI >30 kg/m2) who have comorbidities (eg, dyslipidemia)?
 
Therapeutic lifestyle change
Orlistat
Sibutramine
Weight-loss surgery
Not applicable

12.How familiar are you with the role of the endocannabinoid system in human obesity?
 
Not familiar at all
Somewhat familiar
Moderately familiar
Very familiar
Presented by WebBasedCME.com

Click for a larger image. (Opens in new window)


13.How familiar are you with the effects associated with CB1 receptor blockade?
 
Not familiar at all
Somewhat familiar
Moderately familiar
Very familiar
Presented by WebBasedCME.com

Click for a larger image. (Opens in new window)


14.How familiar are you with the effects of the CB1 antagonists in development?
 
Not familiar at all
Somewhat familiar
Moderately familiar
Very familiar
Presented by WebBasedCME.com

Click for a larger image. (Opens in new window)

Presented by WebBasedCME.com

Click for a larger image. (Opens in new window)

Presented by WebBasedCME.com

Click for a larger image. (Opens in new window)

Presented by WebBasedCME.com

Click for a larger image. (Opens in new window)

Presented by WebBasedCME.com

Click for a larger image. (Opens in new window)

Presented by WebBasedCME.com

Click for a larger image. (Opens in new window)

Presented by WebBasedCME.com

Click for a larger image. (Opens in new window)

Presented by WebBasedCME.com

Click for a larger image. (Opens in new window)

Presented by WebBasedCME.com

Click for a larger image. (Opens in new window)

Presented by WebBasedCME.com

Click for a larger image. (Opens in new window)

Presented by WebBasedCME.com

Click for a larger image. (Opens in new window)


15.How do you prefer to obtain your continuing education credit? Please indicate your first preference in the first list, second preference in the second list, and third preference in the third list.
 
(a). First Preference
Other
(b). Second Preference
Other
(c). Third Preference
Other